Molecular mechanisms of effectiveness of novel therapies in multiple myeloma (Q38035044)

27 August 2017

title

Molecular mechanisms of effectiveness of novel therapies in multiple myeloma (English)

1 reference

27 August 2017

2

Irene M Ghobrial

1 reference

27 August 2017

Giada Bianchi

1

1 reference

27 August 2017

publication date

17 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

54

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

229-241

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

27 August 2017

1 reference

21 January 2018

Pathogenesis of myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Multiple myeloma bone marrow niche

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Humoral immunity and long-lived plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Multiple myeloma: an odyssey of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The unfolded protein response: from stress pathway to homeostatic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Plasma cell differentiation requires the transcription factor XBP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Molecular chaperones in cellular protein folding

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Molecular chaperones in protein folding and proteostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Hsp90 molecular chaperone inhibitors: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Proteostenosis and plasma cell pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Functions of the proteasome: the lysis at the end of the tunnel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

ERAD substrates: which way out?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Proteasome inhibitors: valuable new tools for cell biologists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Latest advances and current challenges in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The role of deubiquitinating enzymes in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Aggresomes and Russell bodies. Symptoms of cellular indigestion?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeting autophagy to fight hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Effect of autophagy on multiple myeloma cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Chemokines in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Expression and function of chemokine receptors in human multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Cellular niches controlling B lymphocyte behavior within bone marrow during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Chemokines in the systemic organization of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Advances in the biology and treatment of bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Multiple myeloma biology: lessons from the 5TMM models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The role of RANK-ligand inhibition in cancer: the story of denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Angiogenesis inhibitors and hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Regulation of the chemokine receptor CXCR4 by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angio

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Lenalidomide mode of action: linking bench and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Hematology: Thalidomide maintenance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Immune therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Risky business in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Molecular pathways: targeting proteasomal protein degradation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Proteasome inhibitors in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeting the UPS as therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Mechanism of action of immunomodulatory agents in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.706287

10.3109/10428194.2012.706287

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference